IGF-DES

IGF-1 DES: Comparative Properties and Advantages

Structural Comparison: IGF-1 DES vs. Standard IGF-1

Structural Modification: IGF-1 DES differs from standard IGF-I through removal of three N-terminal amino acids (Gly-Pro-Glu).

Natural Occurrence: IGF-1 DES occurs naturally in human brain, bovine colostrum, and porcine reproductive tissue, confirming biological relevance.

IGFBP Binding: The Critical Difference

Property

Standard IGF-1

IGF-1 DES

IGFBP Binding Affinity

High

Negligible

Bioavailable Fraction in Circulation

Partial

Nearly Complete

Regulatory Protein Sequestration

Extensive

Minimal

Circulating Half-Life

Shorter

Substantially Extended

Peak Concentration Achievement

Moderate

Elevated

Receptor Availability

Limited

Maximum

Potency Comparison

IGF-1 DES demonstrates approximately 10-fold greater potency than standard IGF-1 in stimulating:

• Muscle hypertrophy and hyperplasia
• Cellular proliferation rates
• Metabolic activity
• Anabolic responses in energy-restricted states

Pharmacokinetic Profile Comparison

Standard IGF-1:

• Rapid IGFBP binding in circulation
• Shorter circulating half-life
• Lower peak concentrations
• Faster metabolic clearance
• Limited sustained action

IGF-1 DES:

• Minimal IGFBP interactions
• Extended circulating persistence
• Substantially elevated peak levels
• Reduced clearance rates
• Prolonged therapeutic action

Metabolic Effects Comparison

Both peptides influence glucose metabolism, but with different magnitudes:

Blood Glucose Reduction:

• Standard IGF-1: Moderate glycemic reduction
• IGF-1 DES: Rapid and pronounced glucose level reduction

Insulin Requirements:

• Standard IGF-1: Modest reduction in insulin needs
• IGF-1 DES: Approximately 10% reduction in insulin requirements in animal models

Anabolic Efficacy:

• Standard IGF-1: Effectiveness reduced under calorie restriction
• IGF-1 DES: Maintained anabolic properties even with restricted caloric intake

Duration of Effect:

• Standard IGF-1: Brief therapeutic window
• IGF-1 DES: Extended therapeutic duration

Neurological Applications Comparison

IGF-1 in Brain Tissue:

• Supports neuronal growth and survival
• Promotes synaptic development
• Maintains cognitive function
• Limited blood-brain barrier penetration

IGF-1 DES in Brain Tissue:

• Superior blood-brain barrier penetration
• Enhanced synaptic transmission (40% increase documented)
• Stronger effects at lower concentrations
• Better accessibility to brain regions

Research Model Comparison

Potency in Pig Studies:

• Standard IGF-1: Baseline growth effects
• IGF-1 DES: Substantially amplified growth effects

Efficacy in Rat Studies (14-day treatment):

• Standard IGF-1: Moderate improvements in body weight and nitrogen balance
• IGF-1 DES: Significant improvements in metabolic parameters

Autism Model Results (5-day treatment):

• Standard IGF-1: Behavioral improvements observed
• IGF-1 DES: Complete reversal of behavioral deficits documented

Immune Function Comparison

Immune Parameter

Standard IGF-1

IGF-1 DES

Neutrophil Activation

Moderate

Superior

Macrophage Function

Effective

More Potent

Pathogen Elimination

Adequate

Enhanced

Intestinal Barrier Support

Yes

Stronger Effect

Mucosal Tissue Growth

Supported

Accelerated

Clinical Application Advantages

For Metabolic Disorders:

• IGF-1 DES works faster and lasts longer
• Potential for Type II diabetes management without insulin's side effects
• Better efficacy in energy-restricted states

For Neurological Conditions:

• IGF-1 DES reaches brain tissue more effectively
• Shows promise for autism spectrum disorders
• Potential for neurodegenerative disease prevention
• Enhanced cognitive benefits in aging populations

For Immune Support:

• IGF-1 DES provides stronger immune enhancement
• Better complement to antimicrobial therapy
• Superior gut barrier maintenance

For Tissue Repair:

• IGF-1 DES accelerates wound healing
• More effective in compromised tissue environments
• Better results in poorly-vascularized areas

Dosimetric Considerations

Standard IGF-1:

• Requires higher doses for equivalent effect
• Shorter dosing intervals
• Greater protein binding reduces effective dose

IGF-1 DES:

• Achieves greater effects at lower concentrations
• Extended duration allows longer dosing intervals
• Complete bioavailability maximizes therapeutic effect
• Excessive dosing paradoxically reduces effectiveness (optimal dosing critical)

Safety and Administration Profile

Both peptides demonstrate:

• Moderate adverse effect potential
• Excellent subcutaneous bioavailability
• Non-translateable animal-to-human dosing

IGF-1 DES demonstrates superior characteristics through:

• Extended therapeutic window
• Greater potency at lower doses
• More sustained biological action
• Better accessibility to protected tissues (brain)

Summary Conclusion

IGF-1 DES provides substantial advantages over standard IGF-1 through enhanced potency, extended duration, superior bioavailability, and superior brain penetration. These advantages position IGF-1 DES as a superior research tool for investigating therapeutic applications across metabolic, neurological, immunological, and tissue regeneration domains.

References

[1] F. J. Ballard, J. C. Wallace, G. L. Francis, L. C. Read, and F. M. Tomas, "Des(1-3)IGF-I: a truncated variant of insulin-like growth factor-I," Int. J. Biochem. Cell Biol., vol. 28, no. 10, pp. 1085–1087, Oct. 1996

[2] F. M. Tomas, P. C. Walton, F. R. Dunshea, and F. J. Ballard, "IGF-I variants that bind minimally to IGF-binding proteins display more potent and extended hypoglycaemic action compared to native IGF-I in pigs and marmoset monkeys," J. Endocrinol., vol. 155, no. 2, pp. 377–386, Nov. 1997

[3] P. E. Walton, F. R. Dunshea, and F. J. Ballard, "In vivo actions of IGF analogues with reduced affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness," Prog. Growth Factor Res., vol. 6, no. 2–4, pp. 385–395, 1995

[4] F. J. Ballard, P. C. Walton, S. Bastian, F. M. Tomas, J. C. Wallace, and G. L. Francis, "Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs," Growth Regul., vol. 3, no. 1, pp. 40–44, Mar. 1993

[5] R. Camboni, "New experimental treatments for core social domain in autism spectrum disorders," Front. Pediatr., vol. 2, p. 61, 2014

[6] J. Costales and A. Kolevzon, "The Therapeutic Potential of Insulin-Like Growth Factor-1 in Central Nervous System Disorders," Neurosci. Biobehav. Rev., vol. 63, pp. 207–222, Apr. 2016

[7] R. Riikonen, "Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children," Int. J. Mol. Sci., vol. 18, no. 10, Sep. 2017

[8] A. B. Steinmetz, S. A. Stern, S. A. Kohtz, G. Descalzi, and C. M. Alberini, "Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice," J. Neurosci. Off. J. Soc. Neurosci., vol. 38, no. 4, pp. 1015–1029, 24 2018

[9] D. Ebrahim-Fakhari and M. Sahin, "Autism and the synapse: emerging mechanisms and mechanism-based therapies," Curr. Opin. Neurol., vol. 28, no. 2, pp. 91–102, Apr. 2015

[10] D. C. Gómedo, M. Beresiewicz, and B. Zablocka, "Neuroprotective effects of short peptides derived from the insulin-like growth factor 1," Neurochem. Int., vol. 51, no. 8, pp. 451–458, Dec. 2007

[11] M. M. Ramsey, M. M. Adams, O. J. Ariwodola, W. E. Sonntag, and J. L. Weiner, "Functional characterization of des-IGF-1 action at excitatory synapses in the CA1 region of rat hippocampus," J. Neurophysiol., vol. 94, no. 1, pp. 247–254, Jul. 2005

[12] X. Zhao, B. W. McBride, L. M. Trouten-Radford, and J. H. Burton, "Effects of intramuscular injection of insulin-like growth factor analogues on bovine hydrothermal protein release by neutrophils and basophils by mononuclear cells," J. Endocrinol., vol. 139, no. 2, pp. 245–252, Nov. 1993

[13] M. E. Yaleman, D. C. Clattey, S. C. Ceyfen-Hughes, V. J. Frost, J. A. Ward, and J. M. Holly, "Cytokines modulate the sensitivity of human fibroblasts to stimulation by insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production," J. Endocrinol., vol. 137, no. 1, pp. 151–159, Apr. 1993

[14] M. Ramade-Bonnet, F. Gamouille, F. al Alie, M. Roccanilora, J. Menville, and G. Perilliere, "Effects of IGF-I and IGF-I on insulin-like growth factor-I/insulin receptor and its potential IGF-II autocrine loop, promotes the differentiation of human colon cancer cells," Int. J. Cancer, vol. 52, no. 3, pp. 457–473, Oct. 1992

[15] J Clin Invest. 2004;113(1):25-27. https://doi.org/10.1172/JCI200420660.